The latest disclosures regarding executive transactions at IONIS PHARMACEUTICALS INC (NASDAQ:IONS) provide an updated view into internal activity, as reported in filings with the SEC. Specifically, director Spencer R. Berthelsen executed a series of trades that involved both selling existing shares and acquiring new ones through option exercises.
On June 1, 2026, Mr. Berthelsen sold 8,000 shares of the company's common stock. The total value realized from this direct sale amounted to $605,360, with each share transacting at a price of $75.67. This disposition of shares was not arbitrary; it was executed pursuant to a Rule 10b5-1 trading plan that Mr. Berthelsen had initially adopted on September 12, 2025.
In contrast to the sale, Mr. Berthelsen simultaneously increased his holdings by acquiring another 8,000 shares. This acquisition resulted from the exercise of non-qualified stock options. These options were valued at $195,360 and carried an exercise price of $24.42 per share. Details regarding these specific options showed that they had been originally granted with an exercise date of July 1, 2017, and held an expiration date set for June 30, 2026.
These reported transactions were formally submitted via a Form 4 filing to the SEC on June 3, 2026. Following the combined activity, Mr. Berthelsen's direct ownership of IONIS PHARMACEUTICALS common stock reached 156,013 shares. Furthermore, his reporting included an indirect holding of 70 shares held by his daughter, though he explicitly disclaimed beneficial ownership of these particular securities.
While the trading activity provides insight into Mr. Berthelsen's portfolio management, broader company news suggests ongoing strategic and clinical momentum for Ionis Pharmaceuticals. The company recently announced a significant development concerning its Alzheimer’s drug, diranersen. Biogen has agreed to advance this medication to registrational development following positive results obtained during a Phase 2 study. This particular study encompassed 416 participants diagnosed with early-stage Alzheimer’s disease and tracked the effects of various doses of diranersen over an extended period of 76 weeks.
In addition to these clinical milestones, Ionis also provided an update on its financial expectations. The company raised its full-year revenue guidance for 2026, adjusting the projected range from a previous estimate of $800 million to $825 million up to a new target of $875 million to $900 million.
The market reception to these updates has been notable among analysts. Oppenheimer responded by increasing its price target for Ionis to $110, while maintaining an Outperform rating. Concurrently, Stifel adjusted its own price target to $86 from $83. This revision was attributed by Stifel to Ionis's strategic pricing adjustments planned for Tryngolza, anticipating potential approval for a larger patient population. Meanwhile, H.C. Wainwright maintained a Buy rating with a $125 price target, citing positive Phase 3 data that came out from GlaxoSmithKline’s treatment for hepatitis B. Rounding out the coverage, Wolfe Research reiterated an Outperform rating alongside a $98 price target, while also noting upcoming data releases from a rival company that could potentially impact Ionis.
From an investment perspective, it is important to note that as of the time of reporting, IONIS shares were trading at $73.82, which represented a substantial 112% gain over the preceding year. However, analysis provided by InvestingPro suggested that, relative to its Fair Value estimate, the stock currently appeared to be overvalued.
Risks
- Market valuation concern: InvestingPro analysis indicated that the stock currently appears overvalued relative to its Fair Value estimate.
- Competitive data risk: Wolfe Research noted upcoming data from a rival company that could potentially impact Ionis's market position.
- Clinical trial uncertainty: The success of future clinical advancements, such as those for diranersen or other treatments, remains contingent on positive outcomes.
More from Insider Trading
Risks
- Market valuation concern: InvestingPro analysis indicated that the stock currently appears overvalued relative to its Fair Value estimate.
- Competitive data risk: Wolfe Research noted upcoming data from a rival company that could potentially impact Ionis's market position.
- Clinical trial uncertainty: The success of future clinical advancements, such as those for diranersen or other treatments, remains contingent on positive outcomes.